288:
66:
236:
102:
25:
407:
467:(NSAID). Otenaproxesul is being developed as a safer non-opiod analgesic for acute pain. Antibe is targeting the post-operative pain market and plans to broaden its application to include migraines, dysmenorrhea and dental pain. Unlike standard naproxen, Otenaproxesul does not induce damage to the
489:
On March 20, 2018, Antibe
Therapeutics announced successful results for Phase 2B gastrointestinal safety study for Otenaproxesul. On June 1, 2020, Antibe announced positive results for Otenaproxesul in its final Phase 2 trial – a dose ranging, efficacy study. The company's second drug, an
982:
957:
696:
755:
907:
1222:
1227:
725:
932:
614:
112:
486:. In mid-January 2015, the company announced that clinical trials for Otenaproxesul were being suspended due to safety concerns; clinical trials were restarted in March 2015.
448:
to sites of inflammation within the human body. Hydrogen sulfide has been shown to enhance the resolution of injury and repair of damage arising from tissue inflammation.
978:
953:
843:
Wallace, John L.; Nagy, Peter; Feener, Troy D.; Allain, Thibault; Ditrói, Tamás; Vaughan, David J.; Muscara, Marcelo N.; Nucci, Gilberto; Buret, Andre G. (February 2019).
686:
747:
575:
903:
1217:
1007:
717:
928:
1028:
126:
of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be
818:
464:
38:
1050:
1192:
1212:
456:
215:
197:
52:
1104:
979:"Antibe Therapeutics Announces Positive Top-Line Data from Phase 2B Dose-Ranging, Efficacy Study for ATB-346 – Antibe Therapeutics"
954:"Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study for Lead Pain Drug, ATB-346 – Antibe Therapeutics"
1075:
845:"A proof-of-concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide-releasing anti-inflammatory drug"
178:
150:
123:
1129:
1197:
157:
119:
387:
135:
780:
249:
164:
548:
534:
146:
493:
On
November 12, 2020, Antibe Therapeutics has moved to the TSX. In February 2021, Antibe announced a deal with
475:
383:
44:
1003:
360:, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the
641:
274:
468:
365:
263:
748:"Antibe Therapeutics Receives FDA Clearance of IND Application for Otenaproxesul for Osteoarthritis Pain"
415:
929:"Antibe Therapeutics Provides an Update on its Data Review and Corporate Strategy – Antibe Therapeutics"
589:
517:
369:
1158:
131:
665:
524:
375:
On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug
361:
287:
127:
904:"Antibe Therapeutics Announces First Human Dose of ATB-346 in Phase I Clinical Trial - MarketWatch"
626:
555:
494:
441:
393:
In May 2024 the company went bankrupt and its stock was delisted from the
Toronto Stock Exchange.
571:
425:
171:
1046:
874:
824:
814:
530:
490:
opioid-replacement for post-surgical pain, is expected to start clinical trials in late 2023.
235:
864:
856:
806:
445:
349:
634:
610:
582:
353:
316:
891:
1096:
622:
Robert
Hoffman, former CFO, Heron Therapeutics; Director, public biotechnology companies
79:
Please help update this article to reflect recent events or newly available information.
1125:
1071:
869:
844:
691:
501:
483:
1191:
Biotechnology Focus: The Need for a Safer NSAID: Can Antibe
Therapeutics Deliver One?
1206:
1198:
Third
International Conference on Hydrogen Sulfide in Biology and Medicine (H2S 2014)
561:
479:
452:
420:
376:
257:
1196:
Third
International Conference on Medical & Biological Uses of Hydrogen Sulfide
345:
810:
601:
504:
company, entitling them to $ 100 million in funding, with $ 20 million upfront.
368:
in
November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in
605:
718:"Antibe's Non-Opioid Pain Drug Otenaproxesul Looks Good in Phase IIb Trials"
631:
Jennifer McNealey, VP Investor
Relations and Strategy, Calithera Biosciences
1126:"Knight Therapeutics – Building a leading specialty pharmaceutical company"
878:
828:
776:
805:. Handbook of Experimental Pharmacology. Vol. 230. pp. 165–180.
460:
860:
1004:"Antibe Therapeutics Provides Corporate Update – Antibe Therapeutics"
498:
482:, the company announced the first human dosing for Phase I of its
357:
344:
was a
Toronto-based pharmaceutical company that develops pain and
319:, Chief Scientific Officer; Joseph Stauffer, Chief Medical Officer
118:
Please help to demonstrate the notability of the topic by citing
1150:
565:
541:
400:
95:
59:
18:
1183:
478:
on Otenaproxesul. In late June 2014, following approval from
328:
1029:"Antibe Therapeutics inks licensing deal with Nuance Pharma"
803:
Chemistry, Biochemistry and Pharmacology of Hydrogen Sulfide
801:
Bhatia, Madhav (2015). "H2S and Inflammation: An Overview".
661:
568:, Los Angeles, USA - 1998 Nobel Prize Laureate in Medicine
474:
In May 2014, the company announced that it had completed
1223:
Companies formerly listed on the Toronto Stock Exchange
444:
of Antibe's drugs is the delivery of minute amounts of
892:
https://www.wsj.com/article/PR-CO-20140505-901386.html
1228:
Companies formerly listed on the TSX Venture Exchange
615:
Barts and The London School of Medicine and Dentistry
113:
notability guidelines for companies and organizations
323:
309:
295:
280:
270:
255:
245:
1047:"Scientific Advisory Board – Antibe Therapeutics"
459:), is a hydrogen sulfide-releasing derivative of
637:, Chief Scientific Officer, Antibe Therapeutics
576:University of Texas Southwestern Medical Center
1097:"Mastercard Incorporated - Investor Relations"
777:"Why Hydrogen Sulfide? – Antibe Therapeutics"
8:
228:
414:It has been suggested that this section be
53:Learn how and when to remove these messages
1072:"Board of Directors – Antibe Therapeutics"
286:
234:
227:
868:
554:Richard H. Hunt, MD, Emeritus Professor,
216:Learn how and when to remove this message
198:Learn how and when to remove this message
315:Dan Legault JD, CEO; Alain Wilson, CFO;
653:
752:American Council on Science and Health
722:American Council on Science and Health
625:Amal Khouri, VP Business Development,
619:Dan Legault, CEO, Antibe Therapeutics
540:Peter B. Ernst, DVM, PhD, Professor,
418:out into another article titled
7:
465:non-steroidal anti-inflammatory drug
455:(formerly ATB-346, now known by its
352:technology. Antibe was founded by
1218:Pharmaceutical companies of Canada
728:from the original on June 26, 2021
588:Philip M. Sherman, MD, Professor,
386:application was cleared by the US
14:
523:Giuseppe Cirino, PhD, Professor,
512:Antibe's science advisory board:
457:International Nonproprietary Name
34:This article has multiple issues.
841:British Journal of Pharmacology
405:
100:
64:
23:
1161:from the original on 2021-11-19
1132:from the original on 2020-09-25
1107:from the original on 2021-11-22
1078:from the original on 2021-08-13
1053:from the original on 2021-08-12
1010:from the original on 2021-05-28
985:from the original on 2021-02-25
960:from the original on 2021-04-16
935:from the original on 2021-04-16
910:from the original on 2014-07-14
783:from the original on 2021-08-12
758:from the original on 2023-06-01
699:from the original on 2017-12-17
668:from the original on 2021-11-17
581:William Sessa, PhD, Professor,
111:may not meet Knowledge (XXG)'s
42:or discuss these issues on the
547:Derek Gilroy, PhD, Professor,
382:On March 29, 2021, the drug's
1:
596:Antibe's board of directors:
390:, allowing for human trials.
364:in 2013 and was moved to the
388:Food and Drug Administration
811:10.1007/978-3-319-18144-8_8
516:Andre G. Buret, Professor,
250:Publicly traded corporation
240:Logo of Antibe Therapeutics
1244:
549:University College, London
120:reliable secondary sources
109:The topic of this article
16:Pharmaceutical corporation
348:-reducing drugs based on
233:
73:This article needs to be
1213:Drug discovery companies
606:MasterCard International
384:Investigational New Drug
229:Antibe Therapeutics Inc.
1155:MaRS Discovery District
1101:investor.mastercard.com
1033:www.biospectrumasia.com
642:MaRS Discovery District
535:University of São Paulo
356:, also a co-founder of
613:, Professor Emeritus,
533:, MD, PhD, Professor,
469:gastrointestinal tract
366:Toronto Stock Exchange
662:"Antibe Therapeutics"
590:University of Toronto
518:University of Calgary
484:human clinical trials
370:regenerative medicine
147:"Antibe Therapeutics"
525:University of Naples
476:pre-clinical studies
451:Antibe's lead drug,
362:TSX Venture Exchange
284:1 January 2010
627:Knight Therapeutics
556:McMaster University
442:mechanism of action
342:Antibe Therapeutics
317:Dr. John L. Wallace
230:
1074:. 28 August 2019.
779:. 21 August 2019.
724:. August 5, 2020.
572:Daniel K. Podolsky
463:, a commonly used
115:
1006:. 4 August 2020.
956:. 20 March 2018.
931:. 11 March 2015.
861:10.1111/bph.14641
820:978-3-319-18143-1
574:, MD, President,
564:, PhD Professor,
531:Gilberto de Nucci
438:
437:
433:
339:
338:
226:
225:
218:
208:
207:
200:
182:
110:
94:
93:
57:
1235:
1187:
1186:
1184:Official website
1170:
1169:
1167:
1166:
1147:
1141:
1140:
1138:
1137:
1122:
1116:
1115:
1113:
1112:
1093:
1087:
1086:
1084:
1083:
1068:
1062:
1061:
1059:
1058:
1049:. 22 July 2019.
1043:
1037:
1036:
1025:
1019:
1018:
1016:
1015:
1000:
994:
993:
991:
990:
975:
969:
968:
966:
965:
950:
944:
943:
941:
940:
925:
919:
918:
916:
915:
900:
894:
889:
883:
882:
872:
839:
833:
832:
798:
792:
791:
789:
788:
773:
767:
766:
764:
763:
744:
738:
737:
735:
733:
714:
708:
707:
705:
704:
683:
677:
676:
674:
673:
658:
544:, San Diego, USA
446:hydrogen sulfide
429:
409:
408:
401:
350:gaseous mediator
335:
332:
330:
291:
290:
238:
231:
221:
214:
203:
196:
192:
189:
183:
181:
140:
104:
103:
96:
89:
86:
80:
68:
67:
60:
49:
27:
26:
19:
1243:
1242:
1238:
1237:
1236:
1234:
1233:
1232:
1203:
1202:
1182:
1181:
1179:
1174:
1173:
1164:
1162:
1149:
1148:
1144:
1135:
1133:
1124:
1123:
1119:
1110:
1108:
1095:
1094:
1090:
1081:
1079:
1070:
1069:
1065:
1056:
1054:
1045:
1044:
1040:
1027:
1026:
1022:
1013:
1011:
1002:
1001:
997:
988:
986:
977:
976:
972:
963:
961:
952:
951:
947:
938:
936:
927:
926:
922:
913:
911:
902:
901:
897:
890:
886:
842:
840:
836:
821:
800:
799:
795:
786:
784:
775:
774:
770:
761:
759:
746:
745:
741:
731:
729:
716:
715:
711:
702:
700:
685:
684:
680:
671:
669:
660:
659:
655:
650:
635:John L. Wallace
611:Roderick Flower
583:Yale University
510:
434:
431:(February 2021)
410:
406:
399:
354:John L. Wallace
327:
312:
305:
301:
285:
275:Pharmaceuticals
260:
241:
222:
211:
210:
209:
204:
193:
187:
184:
141:
139:
117:
105:
101:
90:
84:
81:
78:
69:
65:
28:
24:
17:
12:
11:
5:
1241:
1239:
1231:
1230:
1225:
1220:
1215:
1205:
1204:
1201:
1200:
1194:
1178:
1177:External links
1175:
1172:
1171:
1142:
1117:
1088:
1063:
1038:
1020:
995:
970:
945:
920:
895:
884:
855:(4): 769–777.
849:Br J Pharmacol
834:
819:
793:
768:
754:. 2021-03-21.
739:
709:
692:Bloomberg News
678:
652:
651:
649:
646:
645:
644:
640:Yung Wu, CEO,
638:
632:
629:
623:
620:
617:
608:
604:, Vice Chair,
594:
593:
586:
579:
569:
559:
552:
545:
538:
528:
521:
509:
506:
502:pharmaceutical
436:
435:
413:
411:
404:
398:
395:
337:
336:
325:
321:
320:
313:
310:
307:
306:
303:
299:
297:
293:
292:
282:
278:
277:
272:
268:
267:
261:
256:
253:
252:
247:
243:
242:
239:
224:
223:
206:
205:
188:September 2023
108:
106:
99:
92:
91:
72:
70:
63:
58:
32:
31:
29:
22:
15:
13:
10:
9:
6:
4:
3:
2:
1240:
1229:
1226:
1224:
1221:
1219:
1216:
1214:
1211:
1210:
1208:
1199:
1195:
1193:
1190:
1189:
1188:
1185:
1176:
1160:
1156:
1152:
1146:
1143:
1131:
1127:
1121:
1118:
1106:
1102:
1098:
1092:
1089:
1077:
1073:
1067:
1064:
1052:
1048:
1042:
1039:
1034:
1030:
1024:
1021:
1009:
1005:
999:
996:
984:
981:. June 2020.
980:
974:
971:
959:
955:
949:
946:
934:
930:
924:
921:
909:
905:
899:
896:
893:
888:
885:
880:
876:
871:
866:
862:
858:
854:
850:
846:
838:
835:
830:
826:
822:
816:
812:
808:
804:
797:
794:
782:
778:
772:
769:
757:
753:
749:
743:
740:
727:
723:
719:
713:
710:
698:
694:
693:
688:
682:
679:
667:
663:
657:
654:
647:
643:
639:
636:
633:
630:
628:
624:
621:
618:
616:
612:
609:
607:
603:
599:
598:
597:
591:
587:
584:
580:
577:
573:
570:
567:
563:
562:Louis Ignarro
560:
557:
553:
550:
546:
543:
539:
536:
532:
529:
526:
522:
519:
515:
514:
513:
507:
505:
503:
500:
496:
495:Nuance Pharma
491:
487:
485:
481:
480:Health Canada
477:
472:
470:
466:
462:
458:
454:
453:Otenaproxesul
449:
447:
443:
432:
427:
423:
422:
421:Otenaproxesul
417:
412:
403:
402:
396:
394:
391:
389:
385:
380:
378:
377:Otenaproxesul
373:
371:
367:
363:
359:
355:
351:
347:
343:
334:
326:
322:
318:
314:
308:
298:
294:
289:
283:
279:
276:
273:
269:
265:
262:
259:
254:
251:
248:
244:
237:
232:
220:
217:
202:
199:
191:
180:
177:
173:
170:
166:
163:
159:
156:
152:
149: –
148:
144:
143:Find sources:
137:
133:
129:
125:
121:
114:
107:
98:
97:
88:
76:
71:
62:
61:
56:
54:
47:
46:
41:
40:
35:
30:
21:
20:
1180:
1163:. Retrieved
1154:
1151:"About MaRS"
1145:
1134:. Retrieved
1120:
1109:. Retrieved
1100:
1091:
1080:. Retrieved
1066:
1055:. Retrieved
1041:
1032:
1023:
1012:. Retrieved
998:
987:. Retrieved
973:
962:. Retrieved
948:
937:. Retrieved
923:
912:. Retrieved
898:
887:
852:
848:
837:
802:
796:
785:. Retrieved
771:
760:. Retrieved
751:
742:
732:November 23,
730:. Retrieved
721:
712:
701:. Retrieved
690:
681:
670:. Retrieved
656:
595:
511:
492:
488:
473:
450:
439:
430:
419:
392:
381:
374:
346:inflammation
341:
340:
331:.antibethera
296:Headquarters
246:Company type
212:
194:
185:
175:
168:
161:
154:
142:
85:January 2021
82:
74:
50:
43:
37:
36:Please help
33:
602:Walt Macnee
124:independent
1207:Categories
1165:2021-11-23
1136:2021-11-23
1111:2021-11-23
1082:2021-11-23
1057:2021-11-23
1014:2021-11-23
989:2021-11-23
964:2021-11-23
939:2021-11-23
914:2014-06-27
787:2021-11-23
762:2023-06-01
703:2021-11-23
672:2021-11-23
648:References
311:Key people
266:: ATE
158:newspapers
132:redirected
39:improve it
258:Traded as
122:that are
45:talk page
1159:Archived
1130:Archived
1105:Archived
1076:Archived
1051:Archived
1008:Archived
983:Archived
958:Archived
933:Archived
908:Archived
879:30834513
829:26162834
781:Archived
756:Archived
726:Archived
697:Archived
687:"Stocks"
666:Archived
600:Chair -
592:, Canada
558:, Canada
537:, Brazil
520:, Canada
461:naproxen
397:Products
271:Industry
870:7024706
527:, Italy
499:Chinese
426:Discuss
324:Website
300:Toronto
281:Founded
172:scholar
136:deleted
75:updated
877:
867:
827:
817:
508:People
304:Canada
174:
167:
160:
153:
145:
128:merged
585:, USA
578:, USA
416:split
358:NicOx
179:JSTOR
165:books
134:, or
875:PMID
825:PMID
815:ISBN
734:2021
566:UCLA
551:, UK
542:UCSD
497:, a
440:The
333:.com
151:news
865:PMC
857:doi
853:177
807:doi
424:. (
329:www
264:TSX
1209::
1157:.
1153:.
1128:.
1103:.
1099:.
1031:.
906:.
873:.
863:.
851:.
847:.
823:.
813:.
750:.
720:.
695:.
689:.
664:.
471:.
428:)
379:.
372:.
302:,
130:,
48:.
1168:.
1139:.
1114:.
1085:.
1060:.
1035:.
1017:.
992:.
967:.
942:.
917:.
881:.
859::
831:.
809::
790:.
765:.
736:.
706:.
675:.
219:)
213:(
201:)
195:(
190:)
186:(
176:·
169:·
162:·
155:·
138:.
116:.
87:)
83:(
77:.
55:)
51:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
